deltatrials
Unknown NA NCT00398437

Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer

Role of Gadolinium Enhanced Brain Magnetic Resonance in the Follow Up of Metastatic Breast Cancer Patients Overexpressing HER2 Neu. A Randomized Prospective Study

Sponsor: Jules Bordet Institute

Conditions Breast Cancer Metastatic Cancer
Interventions chemotherapy magnetic resonance imaging trastuzumab
Updated 5 times since 2017 Last updated: Aug 9, 2013 Started: Sep 30, 2006

A NA clinical study on Breast Cancer and Metastatic Cancer, this trial is ongoing. The trial is conducted by Jules Bordet Institute and has accumulated 5 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown NA

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status NA

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status NA

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status NA

    First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jules Bordet Institute
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Brussels, Belgium